fbpx

QQQ
+ 0.00
374.98
+ 0%
BTC/USD
-1369.34
64632.07
-2.07%
DIA
-0.02
356.05
-0.01%
SPY
+ 0.01
452.40
+ 0%
TLT
+ 0.00
142.73
+ 0%
GLD
+ 0.01
166.89
+ 0.01%

Congress Agrees On Funding For FDA Enforcement Of Hemp CBD Products

December 17, 2019 6:42 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Congress Agrees On Funding For FDA Enforcement Of Hemp CBD Products

Federal lawmakers have agreed on a $1.4-trillion government-wide 2020 spending package. The package contains two spending bills, one of which touches on hemp-derived CBD and provides the FDA and USDA with $2 million for research, policy evaluation, market surveillance and issuance of an enforcement discretion policy.

Last year saw the longest-running government shutdown in U.S. history. To avoid a repeat in 2020, the House and Senate have settled on an appropriations bill that passed a House vote this week and is expected to clear the Senate soon. 

Fiscal year 2020 began Oct. 1. By that date, lawmakers are expected to enact a federal spending budget that appropriates federal spending funds to all 12 appropriations subcommittees.

Like every year since 1997, an agreement wasn’t achieved by the Oct. 1 deadline, so the government is relying on temporary measures to keep afloat until Dec. 20, when a government shutdown will begin if an agreement is not in place. 

The legislation instructs the FDA to develop a policy of enforcement discretion for hemp products containing CBD. The agency is also instructed to conduct a market-wide research of CBD products and perform a sample study that analyzes products against their labeled contents.

“While providing funding for testing is a positive first step, unfortunately, today’s action falls short of what is needed to protect consumers. The future of the U.S. hemp industry and the farmers and producers who provide it are directly tied to smart regulations for CBD, which includes FDA establishing a safe level of consumption so consumers are protected,” said Daniel Fabricant, Ph.D., the president and CEO of the Natural Products Association.

More resources should be allocated to CBD regulation in order to avoid a public health crisis like the one tied to vaping, in Fabricant's view. 

Photo by Darren Halstead on Unsplash.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

FDA Will Use Reddit To Learn More About Cannabis-Derived Products Including CBD And Delta 8

FDA Will Use Reddit To Learn More About Cannabis-Derived Products Including CBD And Delta 8

The Food and Drug Administration (FDA) announced that it plans to use Reddit and other data sources to gain a better understanding of public health issues surrounding use of CBD and other cannabis-derived products (CDP). read more
HempFusion's Stock Slightly Up On Announcing Sagely Naturals' Launch Into Top 10 US Retail Outlets

HempFusion's Stock Slightly Up On Announcing Sagely Naturals' Launch Into Top 10 US Retail Outlets

HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB:8OO) announced Wednesday that its wholly-owned subsidiary, Sagely Enterprises, Inc., has launched four SKUs of over the counter topical pain relief products exclusively into a Top 10 US publicly listed Food, Drug & Mass retailer in over 1 read more
What Is Cannabis 3.0? CBD As Trojan Horse? Industry Experts Discuss The Future Landscape of Cannabis Brands

What Is Cannabis 3.0? CBD As Trojan Horse? Industry Experts Discuss The Future Landscape of Cannabis Brands

Speaking at last week’s  Benzinga Cannabis Capital Conference in New York City, Mary Ellen read more
Evogene's Canonic Launches First Two Medical Cannabis Products In Israel Ahead Of Schedule

Evogene's Canonic Launches First Two Medical Cannabis Products In Israel Ahead Of Schedule

Evogene Ltd.'s (NASDAQ: EVGN) (TASE: EVGN) wholly-owned subsidiary focused on developing medical cannabis products, Canonic Ltd., announced the full commercial launch of its first two medical cannabis inflorescence products, known as G200 and G150. read more